Lukasma (Montelukast) is generally used as part of the management plan in the long-term, preventative management of conditions generally linked to chronic respiratory and allergic inflammatory states. The medication is commonly applied across three primary therapeutic domains and is relevant in clinical settings marked by increased discomfort or tension.

Its main uses include the daily management of chronic asthma, providing supportive symptomatic relief for both seasonal and perennial allergic rhinitis, and the prophylaxis of Exercise-Induced Bronchoconstriction (EIB).

Long-Term Control and Symptom Relief

Lukasma is considered relevant for the daily management of chronic asthma by addressing inflammatory or irritative states. It is applied to help with symptoms that may become more disruptive during flare-ups, such as wheezing, coughing, and chest tightness, and contributes to easing discomfort caused by allergic rhinitis symptoms like sneezing and nasal congestion. It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Respiratory Symptoms	Symptom Type	Application
Asthma	Helps manage persistence of coughing and wheezing.
Allergy	Contributes to easing discomfort from runny and stuffy nose.
EIB	Supports the maintenance of open airways prior to activity.

Regulatory References

1. NIH MedlinePlus Drug Information on Montelukast

Lukasma (Montelukast sodium) eligibility is strictly defined by regulatory guidelines. The medicine is absolutely contraindicated in patients with a known hypersensitivity to Montelukast or its components. It must not be used for the reversal of an acute asthma attack, as it is not indicated for immediate relief.

Age- and Condition-Specific Eligibility

Eligibility varies based on age and indication: Lukasma is approved for asthma prophylaxis starting at 12 months of age and for perennial allergic rhinitis starting at 6 months of age. Prevention of exercise-induced bronchoconstriction is approved for patients 6 years of age and older. Efficacy is not established for infants below these minimum age thresholds.

Population Restrictions

No dosage adjustment is recommended for patients with renal impairment or mild-to-moderate hepatic impairment. However, use in patients with severe hepatic impairment has not been evaluated in regulatory documents. During pregnancy and lactation, use is permitted only if considered to be clearly essential. Patients with aspirin sensitivity must continue to avoid aspirin while on Lukasma. For allergic rhinitis, use may be reserved for patients who cannot tolerate or are inadequately treated with alternative medicines.

Lukasma (containing the active ingredient montelukast) is metabolized by specific liver enzymes, primarily Cytochrome P450 (CYP) enzymes CYP 3A4, 2C8, and 2C9. Medicinal products that induce or inhibit these enzymes may affect the concentration of montelukast in the body.

Documented Interactions

Category	Specific Interacting Medicines	Interaction Effect/Condition
CYP Enzyme Inducers	Phenytoin, Phenobarbital, Rifampicin	May decrease the systemic exposure of montelukast. Caution is advised, particularly in children.
CYP Enzyme Inhibitors	Gemfibrozil (CYP 2C8/2C9 inhibitor)	Significantly increases the systemic exposure of montelukast. Routine dose adjustment is not required, but potential for increased adverse reactions should be considered.
Corticosteroids	Oral or Inhaled Corticosteroids	Montelukast must not be abruptly substituted for inhaled or oral corticosteroids.
Pain Relievers	Aspirin, NSAIDs	Patients with documented aspirin sensitivity must continue to avoid aspirin or other non-steroidal anti-inflammatory agents while taking montelukast.
Other	Theophylline, Prednisone, Warfarin	Montelukast has been shown to have no clinically significant effect on the pharmacokinetics of these products.

Montelukast should not be used concomitantly with other products containing the same active ingredient. Consult a healthcare professional regarding all co-administered medications.

Lukasma is a combination pharmaceutical agent comprising a selective H1-receptor antagonist, Levocetirizine, and a leukotriene receptor antagonist, Montelukast.

Levocetirizine operates by competitively binding to peripheral Histamine H1 receptors. This interaction prevents the endogenous ligand, histamine, from activating the receptor and initiating the Gq-coupled intracellular signaling cascade, thereby interrupting histamine-mediated processes such as microvascular permeability and smooth muscle contraction.

Montelukast functions as an antagonist at the cysteinyl leukotriene type 1 ( CysLT1) receptor. It specifically inhibits the binding of pro-inflammatory cysteinyl leukotrienes (LTC4, LTD4, LTE4), which are products of the arachidonic acid cascade. Blocking the CysLT1 receptor, which is expressed on airway smooth muscle cells and inflammatory cells, prevents leukotriene-mediated cellular responses, including smooth muscle contraction and eosinophil recruitment. This dual mechanism modulates two distinct inflammatory pathways, resulting in a system-level attenuation of histaminergic and leukotriene-driven tissue processes.

Lukasma (Montelukast sodium) is strictly administered via the oral route as a high-level, once-daily preventative therapy for maintenance treatment. The medicine is not intended for the rapid relief of acute breathing difficulty. No dosage adjustment is typically required for older adults or patients with mild-to-moderate renal or hepatic impairment.

Administration and Dosing

The medicine is available in three distinct oral forms, with the specific strength determined by age: a 10 mg film-coated tablet for adults and adolescents age 15 years, and 5 mg or 4 mg chewable tablets or 4 mg oral granules for younger children.

The official instructions mandate that the daily dose for asthma or combined asthma/allergic rhinitis must be taken in the evening. For allergic rhinitis alone, the dose can be individualized for morning or evening intake. The administration is generally without regard to mealtimes. If a dose is missed, the user should skip the missed dose and resume the schedule at the next regular time; a double dose should not be taken.

Special Procedural Requirements

Specific handling is required for certain forms: Chewable tablets must be chewed prior to swallowing. If using the oral granules, the contents must be administered within 15 minutes of opening the packet, either placed directly in the mouth or mixed with a spoonful of specified soft foods or liquids, such as applesauce. Furthermore, a patient already taking a daily dose should not take an additional 10 mg for Exercise-Induced Bronchoconstriction (EIB) within the same 24-hour period.

Lukasma: Recent Clinical Evidence

Recent clinical research on the combination drug Lukasma (Montelukast and Levocetirizine) primarily focuses on its use for allergic rhinitis (AR), particularly in patients who also have co-existing asthma.

Efficacy Studies

Systematic reviews and meta-analyses of randomized controlled trials (RCTs) have compared the Lukasma combination therapy to monotherapy with either Montelukast or Levocetirizine alone.

• Symptom Improvement: Studies show that the combination therapy may be associated with greater improvement in certain symptoms of allergic rhinitis, such as daytime nasal symptoms (e.g., congestion and rhinorrhea), compared to using either component by itself. The combined approach aims to target multiple inflammatory pathways involved in allergic responses.
• Asthma Context: In patients with both AR and mild-to-moderate asthma, Phase 3 trials have investigated whether the combination supports positive changes in standard measures of lung function and asthma control when compared to Montelukast monotherapy.

---

Safety and Tolerability

Research has consistently reported that the combination therapy's safety profile is comparable to that of the individual agents used alone.

Adverse Events Reported in Trials
The most commonly documented adverse events across trials include drowsiness, dizziness, headache, and gastrointestinal issues (such as dry mouth or abdominal pain).

Trial data indicate that the overall rate of treatment-emergent adverse events (TEAEs) has been similar between the combination group and the monotherapy groups. Researchers continue to monitor for potential neuropsychiatric effects associated with Montelukast.

Key Studies & References

1. Evaluation of efficacy and safety of montelukast and levocetirizine FDC tablet compared to montelukast and levocetirizine tablet in patients with seasonal allergic rhinitis: a randomized, double blind, multicentre, phase III trial
2. Montelukast: risk of mental disorders vs. efficacy–a meta-analysis (Used for safety profile and neuropsychiatric effects)
3. ZOBIX (Montelukast 10 mg & Levocetirizine Hydrochloride 5 mg Tablets) - NAFDAC Greenbook Admin (Used for general safety profile and adverse events)

Common questions about Lukasma (FAQ)

Q: Are there any specific foods I should avoid while on Lukasma?

Official labeling generally states that this medicine can be taken without regard to mealtimes. However, official documents note that the chewable tablets contain phenylalanine. Patients with phenylketonuria (PKU) are typically advised to take this into account when determining usage. Beyond this consideration, no broad food-avoidance requirements are listed.

Q: Is Lukasma safe to use if I have kidney problems?

Official information indicates that no dosage adjustment is typically required for patients with mild-to-moderate renal impairment. However, the product is contraindicated in patients with severe renal impairment.

Q: Can Lukasma be crushed or mixed with food?

Official instructions specify that chewable tablets must be chewed prior to swallowing, and oral granules may be mixed with specified soft foods or liquids, such as applesauce. The film-coated tablets are described as being swallowed whole, and official instructions do not specify a method for crushing this form.

Q: Does Lukasma have an impact on liver function?

Regulatory documents state that no dosage adjustment is required for patients with mild-to-moderate hepatic (liver) impairment. However, use of the medicine in patients with severe hepatic impairment has not been evaluated in official studies.

Q: Can I mix the oral granules with milk?

Official administration instructions specify that oral granules should be mixed with specified soft foods or liquids, listing applesauce as an example. Since milk is not explicitly listed, official guidelines advise adhering strictly to the mixing options described in the product information.

Q: What does the FDA label say about Lukasma?

The US FDA label carries a Boxed Warning, which is the strongest safety warning, regarding the risk of serious neuropsychiatric events. The label also advises reserving the use of the drug for allergic rhinitis only in patients who have not responded well to or cannot tolerate alternative treatments.

Q: How common is the most severe side effect of Lukasma?

Official product information indicates that the most severe side effects, such as the neuropsychiatric events mentioned in the Boxed Warning, are considered rare. While these events are not common, they are considered serious and require attention if they are noticed.

Q: Can Lukasma cause weight gain?

Weight gain is not listed as a common or frequent side effect in official product labeling. Regulatory documents note that rare adverse events reported in some studies have included some metabolic changes.

Q: Can I take Lukasma with my daily vitamins?

Official drug interaction studies primarily examine how Lukasma interacts with other prescription medicines. Regulatory information consistently advises patients to inform their healthcare provider of all products they are taking, which includes any daily vitamins or supplements.

Q: Is there a generic version of Lukasma available?

Yes, the active ingredient in Lukasma, montelukast, is available in FDA-approved generic versions. This availability is confirmed by regulatory approval documents.

Q: How long does Lukasma stay in your system?

Pharmacokinetic studies cited in official documents indicate that the average plasma half-life of the active ingredient is approximately 2.7 to 5.5 hours in healthy young adults. The half-life is the time it takes for the concentration of the drug in the body to be reduced by half.

Q: Do you have to stop taking Lukasma gradually?

Regulatory guidance addresses the process for discontinuing the drug if neuropsychiatric symptoms occur. If new or worsening symptoms, such as changes in mood or behavior, are noticed, official instructions indicate that the medicine is typically discontinued immediately.

Q: What should I do if I think I'm having a serious side effect from Lukasma?

If a serious side effect, such as a change in mood, behavior, or sleep, is noticed, official instructions indicate that the medication is typically discontinued immediately. Patients are advised to contact a healthcare professional right away for guidance.

Q: Is Lukasma considered a controlled substance?

According to US regulatory authorities, the active ingredient in Lukasma, montelukast, is not classified as a controlled substance.

Q: What should I do if I accidentally take too much Lukasma?

In the event of an overdose or if too much medicine is accidentally taken, official guidance for overdose advises immediate contact with Poison Control or emergency services.

Q: Does Lukasma have different effects based on my gender?

Pharmacokinetic studies detailed in regulatory documents indicate that the body's processing of the active ingredient is similar in males and females. Official labeling concludes that no specific dosage adjustments are required based on gender.

Q: Why is Lukasma a prescription-only medicine?

This medicine is prescription-only because it requires professional diagnosis and individualized dosage management. The need for a prescription is also driven by the necessity for patients to be monitored for potential serious adverse effects, including those noted in the Boxed Warning.

Q: Are there any known interactions between Lukasma and herbal teas?

Specific interactions with herbal teas are not listed in official product labeling. However, regulatory sources consistently advise patients to disclose the use of all supplements, including any herbal products, to their healthcare provider.

Storage Conditions

Lukasma (montelukast sodium) must be stored at a controlled room temperature, specifically not exceeding 30^circC. The medicine must be kept in its original package to ensure protection from light and moisture, as mandated by official labeling. All forms of the medicine must be stored out of the sight and reach of children.

Stability and Handling

Specific stability rules apply to different forms. For tablets packaged in an HDPE bottle, the product must be used within 30 days after the bottle is opened. Lukasma oral granules packets should not be opened until they are ready for administration. If the granules are mixed with food or liquid, the entire dose must be administered within 15 minutes, and any unused mixture must be immediately discarded.

Disposal Instructions

Disposal of any unused or expired Lukasma product must be completed in accordance with local requirements for medicinal waste, as defined by regulatory authorities.